Depts.
Tufts University School of Medicine
136 Harrison Avenue
Boston, MA 02111
Phone:
Email: Bart.Laurijssens@Tufts.edu

Research Interests:

Bart Laurijssens is currently a member of the Clinical Pharmacokinetics/Modelling and Simulation group for Neurology of GlaxoSmithKline in Greenford, UK. Besides being accountable for the pharmacokinetic and pharmacodynamic aspects of the clinical studies for specific projects, he is interested in and responsible for identifying determinants of drug response for these projects. The objective is to capture these determinants in models, and use these models for making predictions to aid decision making and dose selection. This is an ongoing process throughout the lifetime of the compounds: from lead optimisation to market launch. In doing so he is involved in development strategy, disease progression modelling, bio markers assessment, clinical and pre clinical study design, data analysis ((population) pharmacokinetics - pharmacodynamics) and reporting. Currently he is working on compounds in early phases of development (pre-clinical, phase I and phase II) for Alzheimer's Disease, Stroke, and Migraine.

Recent Publications:

Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, Greenblatt DJ. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther. 2002 Sep;302(3):1228-37

Laurijssens BE, Greenblatt DJ. Effect of 7-day exposure to midazolam on electroencephalogram pharmacodynamics in rats: a model to study multiple pharmacokinetic-pharmacodynamic relationships in individual animals. J Pharm Pharmacol. 2002 Jan;54(1):77-86.

Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet. 1996 Jan;30(1):52-76